Klaria Pharma Holding Q1 2023 - No headache just yet

Redeye comments on Klaria Pharma’s Q1 2023 report. The company reports continued validation of its epinephrine alginate film. We regard The Swedish Financial Supervisory Authority´s... | May 16, 2023

Related Keywords

Sweden ,Swedish ,Klaria Pharma ,Swedish Financial Supervisory Authority ,Research Powered Investment Banking ,Life Science ,Powered Investment ,Klaria Pharma Holding Ab Publ Stock Exchange ,News ,Information ,Press Release ,Redeye ,Comments ,N ,Malaria ,1 ,023 ,The ,Company ,Reports ,Ontinued ,Validation ,F ,Its ,Epinephrine ,Alginate ,He ,Regard ,Financial ,Upervisory Klar Se0007280326 ,